Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Grows By 25.5%

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 6,400 shares, an increase of 25.5% from the August 31st total of 5,100 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Pulmatrix in a research note on Monday, September 23rd. They set a “hold” rating for the company.

Pulmatrix Stock Performance

NASDAQ:PULM opened at $2.14 on Monday. The stock has a market capitalization of $7.81 million, a P/E ratio of -0.89 and a beta of 0.99. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The company has a 50 day moving average price of $2.10 and a 200 day moving average price of $1.98.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The firm had revenue of $1.55 million for the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.